Literature DB >> 3238649

The mode of action of heparin in plasma.

S Béguin1, T Lindhout, H C Hemker.   

Abstract

The influence of heparin on prothrombin conversion in plasma was estimated by measuring prothrombin disappearance with the aid of staphylocoagulase or by calculation from the thrombin generation curve, compensating for simultaneous thrombin inactivation by plasma protease inhibitors. In thromboplastin-activated plasma the effect of heparin on prothrombinase (factor Xa-factor Va-phospholipid) is negligible compared to that on thrombin probably because both the extrinsic factor X activating complex and phospholipid bound factor Xa are insensitive to AT III-heparin action. In contact-activated plasma prothrombinase generation is inhibited by heparin, because heparin lowers the ambient concentrations of thrombin so that the feedback activation of factor VIII by thrombin is diminished. Consequently, the delayed factor Xa generation causes a lag phase in prothrombinase generation. We conclude that heparin in plasma acts by its thrombin scavenging properties. No direct action on prothrombinase or on the factor X activating enzyme needs to be assumed if one takes into account the effect of thrombin depletion on thrombin-mediated feedback reactions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3238649

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

1.  Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.

Authors:  X J Yang; M A Blajchman; S Craven; L M Smith; N Anvari; F A Ofosu
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

2.  Issues Regarding the Use of Heparin Following Streptokinase Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.

Authors:  B Bray; D A Lane; J M Freyssinet; G Pejler; U Lindahl
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

4.  Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.

Authors:  F A Ofosu; J W Fenton; J Maraganore; M A Blajchman; X Yang; L Smith; N Anvari; M R Buchanan; J Hirsh
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

Review 5.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

6.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

Review 7.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

8.  Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa.

Authors:  Bianca F Glauser; Ricardo M Rezende; Fabio R Melo; Mariana S Pereira; Ivo M B Francischetti; Robson Q Monteiro; Alireza R Rezaie; Paulo A S Mourão
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

9.  Cerebrovascular Disease in Pregnancy.

Authors:  Salina Waddy; Barney J. Stern
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-07

Review 10.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.